Found: 7
Select item for more details and to access through your institution.
Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 12, p. 5389, doi. 10.1111/bcp.15468
- By:
- Publication type:
- Article
Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.
- Published in:
- Journal of Neurology, 2024, v. 271, n. 10, p. 6655, doi. 10.1007/s00415-024-12616-6
- By:
- Publication type:
- Article
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 1, p. 652, doi. 10.1002/ehf2.13154
- By:
- Publication type:
- Article
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 890, doi. 10.1002/psp4.12663
- By:
- Publication type:
- Article
Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2′‐MOE and Phosphorothioate Modified Antisense Oligonucleotides.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, n. 1, p. 21, doi. 10.1002/jcph.2121
- By:
- Publication type:
- Article
An oral antisense oligonucleotide for PCSK9 inhibition.
- Published in:
- Science Translational Medicine, 2021, v. 13, n. 593, p. 1, doi. 10.1126/scitranslmed.abe9117
- By:
- Publication type:
- Article